meRfi®-GM
Pembrolizumab
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities.…
References (Sources)
- Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
- PembrolizumabReview
- Pembrolizumab: First Global ApprovalReview
- Safety & Efficacy of Pembrolizumab in Advanced, PD-L1 – Positive Cervical Cancer: Results From Phase Ib KEYNOTE-028 Trial
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
- Second- and third-generation drugs for immuno-oncology Treatment - The more the better?